80.09
Bio Rad Laboratories Inc stock is traded at $80.09, with a volume of 1.82M.
It is down -2.50% in the last 24 hours and up +0.00% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$82.14
Open:
$82.38
24h Volume:
1.82M
Relative Volume:
7.39
Market Cap:
$15.69B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-21.38
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
-4.68%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BBIO
Bio Rad Laboratories Inc
|
80.09 | 16.48B | 579.96M | -729.89M | -452.02M | -3.7459 |
|
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BBIO) Latest News
BIO|Bio Rad Laboratories Inc|Price:316.410|Chg%:+1.950 - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIO|Bio Rad Laboratories Inc|Price:314.460|Chg%:-1.760 - TradingKey
TradingKey - TradingKey
Bio-Rad Laboratories (BIO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance Singapore
Bio-Rad Laboratories (BIO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100 - GuruFocus
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - BioSpace
Press Release: Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Bio-Rad will discuss Q2 results at 5 p.m. ET on Aug. 4 - Stock Titan
Bio-Rad to report Q2 2026 results, host conference call - Bitget
Bio-Rad Laboratories stock holds on to year-end earnings context - Ad-hoc-news.de
Bio-Rad Laboratories (BIO) Experiences Minor Decline Amid Compet - GuruFocus
Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide - Sahm
Bio-Rad Q1 2026 Earnings: EPS Misses Estimates by 5.68%, Stock Edges Higher on Resilient Business TrendsRevenue Breakdown Analysis - po-news-eg.net
Diagnostic Reagent Market is Going to Boom: New Report Reveals - openPR.com
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - Yahoo Finance
In Fight With GC, Bio-Rad Adds Quinn Emanuel to Legal Team - Law.com
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad Laboratories (BIO) Surges 4.4% as Bullish Momentum Builds From Key Support LevelOBV Divergence - dars.gov.et
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)? - Yahoo Finance
Elliott Targets Bio-Rad After 70% Stock Collapse - Yahoo Finance
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus - Sahm
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday - Benzinga
Elliott Management Takes Stake in Bio-Rad to Boost Stock Performance (BIO) - GuruFocus
Bio Rad Laboratories Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Rad Laboratories Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ellis Andrea | Director |
Jul 09 '26 |
Sale |
84.00 |
17,167 |
1,442,028 |
22,579 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Option Exercise |
24.96 |
148,589 |
3,708,335 |
156,972 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Sale |
88.54 |
148,589 |
13,156,008 |
8,383 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):